Saudi Arabia pushes ahead with biotech hub despite regional instability

Saudi Arabia is constructing a regulatory framework, partnership networks and intellectual property structures to nurture a biotech ecosystem, even as regional political tensions persist.

Experts note recent regulatory reforms and growing international collaborations have strengthened the Saudi science landscape, and the country’s financial resources support ambitions for a pharmaceutical manufacturing sector.

The next growth phase will rely on clinical trial activity, hospital involvement, IP generation and the development of experienced biotech leaders.

While challenges remain, observers say the outlook for Saudi Arabia’s biotech and manufacturing capabilities appears promising.